Ionis Pharmaceuticals Inc (IONS)
Ionis Pharmaceuticals develops and sells medicines that act on RNA to treat serious diseases, mainly rare genetic conditions. It last closed at $26.96 on Nov 17, down 3.75% on the day. The average 12-month price target from 14 analysts is $69.79 (+158.8% from the last close), with a high of $88.00 and a low of $41.00. Analyst consensus is Strong Buy, based on the latest ratings from 14 firms (13 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in IONS, 100% of them bullish and 0% bearish. In the past 30 days there were 8 dark pool prints totaling $10.3M, the largest $2.2M.
Key Stats
Last 12 monthsNot reported for this period.
From IONS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 14 analysts who set a price target on IONS in the past 90 days. The average target is $69.79, with a high of $88.00 and a low of $41.00, compared with the last close of $26.96.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 10 | Goldman Sachs | Target lowered | Hold | $56 → $41 |
| Nov 10 | Morgan Stanley | Target lowered | Buy | $104 → $75 |
| Nov 10 | TD Cowen | Maintained | Buy | $53 |
| Nov 10 | Oppenheimer | Maintained | Buy | $70 |
| Nov 10 | RBC Capital | Target lowered | Buy | $85 → $60 |
Technical Analysis
The stock is 39% below its 20 day and 58% below its 50 day average. It is 137% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the 52 week low at $26.55, and the nearest resistance the Pivot at $27.20.
| RSI (14) | 21.70 | Oversold below 30 | Oversold |
| MACD | -4.78 | Below its signal line | Bearish |
| Stochastic | 5.3 | Near the bottom of its range | Oversold |
| ADX (14) | 46.2 | Strong downtrend | |
| Williams %R | -97.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -109.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −33.3% | Change over 10 sessions | Bearish |
| ATR (14) | $2.23 | Typical daily range, 8.3% of price |
| RSI (14) | 21.15 | Oversold below 30 | Oversold |
| MACD | -9.28 | Below its signal line | Bearish |
| Stochastic | 3.4 | Near the bottom of its range | Oversold |
| ADX (14) | 39.9 | Trending down | |
| Williams %R | -98.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -173.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −50.3% | Change over 10 sessions | Bearish |
| ATR (14) | $5.53 | Typical daily range, 20.5% of price |
What happened before
See how IONS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IONS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in IONS in the last 90 days.
Dark Pool
30DIONS Institutional Ownership
Full report →- ●241 buying vs 275 selling
- ▼Held by funds -9.0 pts
- ▼Funds holding -54
- ▲Superinvestors: 4 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 472 | 526 | −10.3% |
| In funds' top 10 | 7 | 10 | −30.0% |
| Held by funds | 111.3% | 120.3% | −9.0 pts |
| New / increased | 66 / 175 | 68 / 203 | −11.1% |
| Reduced / sold out | 159 / 116 | 164 / 50 | +28.5% |
| Put/call ratio | 1.57 | 0.40 | +292.7% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IONS is in one of them and how their past IONS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IONS in an article yet. Here's the latest on the wider market.
IONS Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Dan GoldmanD · NY | Sell | $1K – $15K | Mar 6, 2023 | Apr 17, 2023 | 42 d |
| Ro KhannaD · CA | Sell | $1K – $15K | Mar 14, 2023 | Apr 7, 2023 | 24 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Dec 6, 2022 | Jan 3, 2023 | 28 d |
| Donna ShalalaD · FL | Sell | $1K – $15K | Jun 24, 2019 | Apr 27, 2020 | 308 d |
| Donna ShalalaD · FL | Buy | $1K – $15K | May 8, 2019 | Apr 27, 2020 | 355 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California, that develops and sells medicines for serious diseases. Its products act on RNA, the molecule that carries genetic instructions, to lower the production of specific proteins in the body. Its marketed medicines treat conditions such as familial chylomicronemia syndrome, hereditary angioedema, and spinal muscular atrophy. Patients receive these medicines through the company's own sales efforts and through partners such as Biogen and AstraZeneca.
- Headquarters
- Carlsbad, CA








